Supported by a strong talent pool of over 800 qualified scientists of TCG Lifesciences (TCGLS), Clininvent Research Pvt. Ltd., the 100 percent subsidiary of TCGLS, has successfully passed a pre-approval inspection as a manufacturing plant, by the US Food and Drug Administration (USFDA). The inspection confirmed the site to be compliant with the principles and guidelines of Good Manufacturing Practices (GMP).
15 years of strategic collaboration between Grunenthal and TCG Lifesciences
The year 2018 marks the completion of 15 years of strategic collaboration between Grunenthal and TCG Lifesciences. This partnership started in the year 2003 with a simple fee-for-service custom synthesis project and gradually expanded into a sizeable FTE based collaborative working relationship covering a variety of services including Medicinal Chemistry, Process Development, Analytical Development, Library Synthesis, Scale-Up Synthesis as well as an integrated Drug Discovery mode across several therapeutic targets.
As a result, TCG Lifesciences has made a significant contribution to Grünenthal’s R&D activities through high quality, timely and cost effective delivery of new chemical entities across a broad range of drug discovery and development programs.
This exemplary and progressive journey of 15 years is built upon a strong trust-based relationship, effective teamwork and close communications between the scientific teams of both partners.
TCG Lifesciences signs an MOU with NIPER
Novel method of guided arylation
Novel method of guided arylation using new directing group 3- Amino-1-methyl-1H-pyridin-2-one (AMP) via Pd(II) catalyzed C(sp3/sp2)-H activation by TCGLS team, Tanmay Pati, Mrinalkanti Kundu and Uttam Khamrai in collaboration with scientists from the University of Calcutta, Sudipta Debnath and Dilip Maiti . The work is published in highly esteemed ACS journal, Organic Letters (DOI: 10.1021/acs.orglett.8b01618).
NCLT Convened Meeting
NATIONAL COMPANY LAW TRIBUNAL, KOLKATA BENCH, KOLKATA
CA (CAA) No. 564/KB/2018
IN THE MATTER OF :
1. TCG Lifesciences Private Limited, a company incorporated under the Companies Act, 1956. Regd. off: Block-BN, Plot-7, Salt Lake Electronic Complex, Sector-V, Kolkata 700091. …Demerged Company/ First Applicant Company
2. Green Cross Therapeutics Private Limited, a company incorporated under the Companies Act, 1956. Regd. Off.: Bengal Intelligent Park, Ground Floor, Beta Building Block EP&GP, Sector V, Salt Lake Electronics Complex, Kolkata 700091.
… Resulting Company/Second Applicant Company Notice and Advertisement of notice of the meeting of creditors
Notice is hereby given that by an Order dated the 13th day of July 2018, the Kolkata Bench of the National Company Law Tribunal has directed separate meetings to be held of the secured and unsecured creditors of First Applicant Company for the purpose of considering, and if thought fit, approving with or without modification, the proposed arrangement embodied in Scheme of Arrangement between the
Demerged Company and Resulting Company.
In pursuance of the said Orders and as directed therein further notice is hereby given that separate meetings will be held as under :
In relation to Transferor/Demerging Company (TCG Lifesciences Private Limited)
a. Meeting of unsecured creditors shall be held at Block-BN, Plot-7, Salt Lake Electronic Complex, Sector-V Kolkata 700091 on Friday, 31st August 2018 at 11:30 am.
b. Meeting of secured creditors shall be held at Block-BN, Plot-7, Salt Lake Electronic Complex, Sector-V Kolkata 700091 on Friday, 31st August 2018 at 12:30 pm.
Copies of the said Scheme of arrangement and of the explanatory statement under section 230 can be obtained free of charge at the registered office of the companies or at the office of its authorized representative Ms. Sanchari Chakraborty, Advocate at 8/1 Kiron Shankar Roy Road, Kolkata 700 001. Persons entitled to attend and vote at the meeting (or respective meetings), may vote in person or by proxy, provided that all proxies in the prescribed form are deposited at the registered office of the Demerged Company as indicated above not later than 30 minutes
before the meeting.
Forms of proxy can be obtained from the registered office of the Demerged Company. The Tribunal has appointed Shri Arkodeb Sinha, Advocate, as the Chairperson and Mr. Kovid Mukherjee, PCS, as the scrutinizer of the said meetings. The above mentioned Scheme of Arrangement, if approved by the meeting, will be subject to the subsequent approval of the Hon’ble Tribunal. Dated this 19th day of July 2018
Sd./- Arkodeb Sinha, Chairperson
Appointed by the Order of the Hon’ble National Company Law Tribunal, Kolkata
TCG Lifesciences congratulates Curadev for its recent research collaboration and licensing agreement to develop cancer immunotherapeutic candidate
TCG Lifesciences Limited (formerly “Chembiotek Research International”), a leading contract research services company in the area of early drug discovery and development congratulates Curadev Pharma Private Limited for its research collaboration and exclusive license agreement for the development and commercialization of IDO1 and TDO inhibitors.
TCG Lifesciences provided chemistry synthesis of molecules and preliminary scale up of the lead molecule for Curadev.
“Speed is the key to winning,” said Dr.Subho Roy, Associate VP – TCG Lifesciences, “TCG scientists developed innovative synthetic routes with tight cycle times to deliver the lead molecules which were quickly optimized. Subsequently, TCG developed a cost effective route for rapid scale up of the desired API.”
“We applaud Curadev for this achievement,” said Swapan Bhattacharya, Managing Director TCG Lifesciences. “They identified the target long before immuno-oncology became a “red hot” area for cancer therapy and focused tenaciously on this program despite many challenges. Curadev has put India on the map for development of innovative and novel drug candidates at the frontiers of science.”
About TCG Lifesciences
TCG Lifesciences Limited (formerly “Chembiotek Research International”) is a leading contract research services company in the area of early drug discovery and development.It started its operations in the year 2001 in India; currently it has its presence in United States, Europe and Japan. It is part of ‘The Chatterjee Group’, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its units Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with many global pharmaceutical companies which span from specific solutions and sourcing services to integrated projects across multiple domains in the early drug discovery and development space. Learn more at https://tcgls.com
For further information:
Rakesh Pandya, VP Finance, [email protected]
Debiopharm Group™ and TCG Lifesciences Ltd. announce successful completion of first phase of research collaboration on discovery of novel antibiotics
Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including anti-bacterial, oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced that they have reached the first research milestone and consequently enter into lead optimization phase for innovative antibiotics targeting drug-resistant bacteria for community and hospital-acquired infections.
This first step towards identification of new classes of targeted anti-infectious drugs was achieved only 9 months after signature of a discovery collaboration will trigger the payment of research milestones by Debiopharm according to a pre-defined research plan.
Dr Saumitra Sengupta, Distinguished Scientist at TCG Lifesciences commented: “The strong collaborative spirit from both sides has resulted in reaching this important milestone. We are excited about partnering with Debiopharm in their search for new antibiotics and wish to continue in the same spirit of value addition in order to bring this project to a meaningful result.”
“This fruitful collaboration with TCG Lifesciences has now delivered early leads ready to enter into the process of lead optimization”, said Andrés McAllister, Chief Scientific Officer, Debiopharm International SA, who added: “It is an important milestone for Debiopharm, supporting our strong commitment to develop novel antibiotics to overcome resistance to current treatments. It is part of our global strategy initiated with the development of our FabI inhibitors, Debio 1450, currently in clinical Phase I and Debio 1452 which has already demonstrated high efficacy in the treatment of acute bacterial skin and skin-structure infections in a phase II trial.”
About TCG Lifesciences Ltd.
TCGLS is a leading contract research services company in the area of early drug discovery and development. They started their operations in the year 2001 in India. Currently TCGLS is present in the United States, Europe, Japan and Australia. The company has a strong talent pool of 800+ trained scientists, drawn from the best national and international institutes as well as the industry. Their services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases
For more information about TCG, please visit:www.tcgls.com
About Debiopharm Group™
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary d rugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized throughoutlicensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit:www.debiopharm.com
Debiopharm International SA Contact
Christelle Tur Communication Coordinator [email protected] Tel: +41 (0)21 321 01 11
TCG Lifesciences Ltd Contact
Rakesh C. Pandya Head – Finance [email protected] Tel: +91 33 4000 3000
Additional Media Contacts
In London Maitland Brian Hudspith [email protected] Tel: +44 (0)20 7379 5151
In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive [email protected] Tel: +1 212-845-4292
Axcellerate Pharma, New Jersey aims to become a market leader in high-value, niche offerings to the US life sciences industry
Axcellerate Pharma establishes CMO/CRO and API manufacturing facility in New Jersey, US. Focus will be small molecule and biologics PR&D, innovative technology platforms, filling vial and bag operations, peptide synthesis, oligonucleotide production and related areas.
Axcellerate Pharma LLC (“Axcellerate”) is a JV set up by TCG Lifesciences USA LLC, an affiliate of TCG Lifesciences Limited, a leading CRO engaged in drug development and clinical trial services; with Dilip Mehta, Founder & CEO of PANORAMA Consulting and Engineering, Inc., a leading developer of lab scale to GMP manufacturing facilities; and Alfagen Pharma LLC, an affiliate of AlfaGene Bioscience, Inc., an innovative biotechnology company. The facility houses state-of-the-art technology/equipment/ infrastructure and is supported by leading industry personnel from each of the partner firms.
“We will initially target specialized CMC and CMO activities that are time sensitive and high value in nature, that are desirable to be located geographically close to our clients. Axcellerate intends to leverage the strong scientific talent pool, end-to-end capabilities and PR&D/intermediate production facilities of TCG Lifesciences Limited in India to support its operations. This opportunity represents another significant milestone for TCG Lifesciences’ continued expansion,” commented Swapan Bhattacharya, Managing Director of TCG Lifesciences “as this strategic alliance will expand TCG Lifesciences’ geographic footprint and enable us to service clients in the US with a local presence while being supported globally”.
Dilip Mehta, CEO and co-founder of Axcellerate commented “we will engineer the facilities to provide the highest level of efficiency, technology and cost effectiveness to our customers, given PANORAMA’s broad involvement and experience in all facets of the pharma/biotech sector. We are pleased to join hands with TCG Lifesciences, who will bring in the scientific and technical know how and expertise in the cutting edge areas of drug discovery and development.”
“AlfaGene Bioscience has developed proprietary assay platforms in a range of therapeutic indications and has a scientific team with extensive experience in biologics and biomedical research. We also have a network of global relationships in the API arena to bring to bear for the success of Axcellerate”, remarked Mayur Doshi, President and CEO, AlfaGene Bioscience.
About TCG Lifesciences Limited
TCGLS are a leading contract research services company in the area of drug discovery and early development. The company employs 675+ trained scientists, drawn from the best national and international institutes and industry. Their services span from specific discovery, preclinical and clinical development solutions to integrated drug development programs across multiple therapeutic areas of Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases.
For more information about TCG, please visit:www.tcgls.com
About PANORAMA Consulting & Engineering, Inc.
PANORAMA is a full – service EPCMCV (Engineering, Procurement, Construction Management, Commissioning and Validation) company, offering services in the Pharmaceutical, Bio-Pharmaceutical, Nano-Technology, Chemical, Specialty Chemical, Polymer and Petrochemical Industries. Their clients range from Big Pharma to small startups finding their footing in the industry. With a highly qualified and diverse staff well rounded to deal with numerous engineering and project management challenges, Panorama has served major companies, with projects ranging from large-scale facilities to laboratories for drug development purposes. They also provide process development and scale-up services to take your research to the next level and help you through the entire process from inception to mass production.
For more information about Panorama, please visit:www.panoramaus.com
Contact:
Mr. Swapan Bhattachrya([email protected])
Mr. Dilip Mehta ([email protected])
Mr. Sandro La Rosa (([email protected]))
Debiopharm Group™ and TCG Lifesciences Ltd. enter into an exclusive Research agreement to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm
Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including oncology as well as companion diagnostics, and TCG Lifesciences Limited (TCGLS) a leading contract research services company in the area of early drug discovery and development, today announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drugresistant bacteria for community hospital-acquired infections.
Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.
Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.
“We foresee to increase our commitment in this field over next few months through additional partnerships and investments on other innovative targets” said David Deperthes, VP Business Development & Licensing. “We are very enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348. This partnership is key to us to establish a leadership position in the area of antibiotics” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.
Swapan Bhattacharya, Managing Director of TCG Lifesciences commented: “We are indeed excited about this program which involves a challenging new target that could potentially address the vast incidence of nosocomial infections which plague healthcare facilities all over the world. Debiopharm’s developmental expertise combined with our medicinal chemistry capabilities and efficient discovery operations provide an attractive opportunity for accelerated discovery of novel drug candidates for clinical development.”
About TCG Lifesciences Ltd.
TCGLS is a leading contract research services company in the area of early drug discovery and development. They started their operations in the year 2001 in India. Currently TCGLS is present in the United States, Europe, Japan and Australia. The company has a strong talent pool of 800+ trained scientists, drawn from the best national and international institutes as well as the industry. Their services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases. For more information about TCG, please visit: www.tcgls.com
About Debiopharm Group™
Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information about Debiopharm Group™, please visit: www.debiopharm.com.
Debiopharm International SA Contact
Beatrice Hirt
Communication Coordinator
Tel.: +41 (0)21 321 01 11
Additional Media Contacts In London
Maitland
Brian Hudspith
Tel.: +44 (0)20 7379 5151
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1 212-845-4292
TCG Lifesciences Ltd Contact
Rakesh C. Pandya
Head – Finance
Tel.: +91 33 4000 3000
Integrating R&D and cGMP kilo-scale synthesis for new therapeutic products
TCG Lifesciences is a contract research services company headquartered in India and with a worldwide presence offering research support ranging from specific solutions to integrated discovery projects across multiple therapeutic areas. This article describes how the company’s platform technologies and expertise in process development and scale-up provide solutions for the discovery and development of new drug candidates including new chemical entities (NCEs).
.jpg ?>)
.jpg ?>)
